Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01082874




Registration number
NCT01082874
Ethics application status
Date submitted
8/03/2010
Date registered
9/03/2010
Date last updated
25/08/2016

Titles & IDs
Public title
PeriOperative ISchemic Evaluation-2 Trial
Scientific title
A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event
Secondary ID [1] 0 0
2009-018173-31
Secondary ID [2] 0 0
POISE-2 01MAR2010
Universal Trial Number (UTN)
Trial acronym
POISE-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiovascular Disease 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Active Clonidine
Treatment: Drugs - Placebo Clonidine
Treatment: Drugs - Active ASA
Treatment: Drugs - Placebo ASA

Experimental: Active Clonidine and Active ASA -

Experimental: Active Clonidine and Placebo ASA -

Experimental: Placebo Clonidine and Active ASA -

Placebo comparator: Placebo Clonidine and Placebo ASA -


Treatment: Drugs: Active Clonidine
Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.

Treatment: Drugs: Placebo Clonidine
Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.

Treatment: Drugs: Active ASA
Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery

Treatment: Drugs: Placebo ASA
Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Composite of All-cause Mortality and Nonfatal MI
Timepoint [1] 0 0
30 days
Primary outcome [2] 0 0
All-cause Mortality and Nonfatal MI
Timepoint [2] 0 0
1 year
Secondary outcome [1] 0 0
Composite of All-cause Mortality, Nonfatal MI, and Nonfatal Stroke
Timepoint [1] 0 0
30 days
Secondary outcome [2] 0 0
Individual Secondary Outcomes
Timepoint [2] 0 0
30 days
Secondary outcome [3] 0 0
Composite Outcome by ASA Stratum
Timepoint [3] 0 0
30 days
Secondary outcome [4] 0 0
Safety Outcomes in ASA Trial
Timepoint [4] 0 0
30 days
Secondary outcome [5] 0 0
Safety Outcomes in Clonidine Trial
Timepoint [5] 0 0
30 days
Secondary outcome [6] 0 0
Composite Outcome at 1 Year
Timepoint [6] 0 0
1 year
Secondary outcome [7] 0 0
Individual Secondary Outcomes at 1 Year
Timepoint [7] 0 0
1 year

Eligibility
Key inclusion criteria
1. Are undergoing noncardiac surgery;
2. Are = 45 years of age;
3. Are expected to require at least an overnight hospital admission after surgery; AND
4. Fulfill one or more of the following 5 criteria:

* History of coronary artery disease
* History of peripheral vascular disease
* History of stroke
* Undergoing major vascular surgery
* Any 3 of the following 9 criteria:

* undergoing major surgery (i.e. intraperitoneal, intrathoracic, retroperitoneal or major orthopedic surgery
* history of congestive heart failure
* transient ischemic attack
* diabetes and currently taking an oral hypoglycemic agent or insulin
* age = 70 years
* hypertension
* serum creatinine > 175 µmol/L (> 2.0 mg/dL)
* history of smoking within 2 years of surgery
* undergoing urgent/emergent surgery
Minimum age
45 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Consumption of ASA within 72 hours prior to surgery
2. Hypersensitivity or known allergy to ASA or clonidine
3. Systolic blood pressure < 105 mm Hg
4. Heart rate < 55 beats per minute in a patient who does not have a permanent pacemaker
5. Second or third degree heart block without a permanent pacemaker
6. Active peptic ulcer disease or gastrointestinal bleeding within previous 6 weeks
7. Intracranial hemorrhage documented by neuro-imaging, in the 6 months prior to randomization. This does not include petechial hemorrhagic transformation of a primary ischemic stroke
8. Subarachnoid hemorrhage or epidural hematoma unless the event occurred more than 6 months prior to randomization and the offending aneurysm or arterial lesion has been repaired
9. Drug-eluting coronary stent in the year prior to randomization
10. Bare-metal coronary stent in the 6 weeks prior to randomization
11. Thienopyridine (e.g., clopidogrel, ticlopidine, prasugrel) or ticagrelor within 72 hours prior to surgery; or intent to restart a thienopyridine or ticagrelor during the first 7 days post-op; or currently taking an alpha-2 agonist, alpha methyldopa, monoamine oxidase inhibitors or reserpine;
12. Planned use - during the first 3 days after surgery - therapeutic dose anticoagulation or a therapeutic subcutaneous or intravenous antithrombotic agent
13. Undergoing intracranial surgery, carotid endarterectomy, or retinal surgery
14. Not consenting to participate in POISE-2 prior to surgery
15. Previously enrolled in POISE-2 Trial

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Factorial
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2015
Sample size
Target
Accrual to date
Final
10010
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
National Coordination Office Australia and New Zealand - Parkville
Recruitment postcode(s) [1] 0 0
- Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Ohio
Country [2] 0 0
Argentina
State/province [2] 0 0
Rosario
Country [3] 0 0
Austria
State/province [3] 0 0
Vienna
Country [4] 0 0
Belgium
State/province [4] 0 0
Brussels
Country [5] 0 0
Brazil
State/province [5] 0 0
Sao Paulo
Country [6] 0 0
Canada
State/province [6] 0 0
Ontario
Country [7] 0 0
Chile
State/province [7] 0 0
Santiago
Country [8] 0 0
Colombia
State/province [8] 0 0
Bucamaranga
Country [9] 0 0
Denmark
State/province [9] 0 0
Herlev
Country [10] 0 0
France
State/province [10] 0 0
Boulogne-Billancourt
Country [11] 0 0
Germany
State/province [11] 0 0
Bonn
Country [12] 0 0
Hong Kong
State/province [12] 0 0
Hong Kong
Country [13] 0 0
India
State/province [13] 0 0
Bangalore
Country [14] 0 0
Italy
State/province [14] 0 0
Milan
Country [15] 0 0
Malaysia
State/province [15] 0 0
Kuala Lumpur
Country [16] 0 0
New Zealand
State/province [16] 0 0
Auckland
Country [17] 0 0
Pakistan
State/province [17] 0 0
Islamabad
Country [18] 0 0
Peru
State/province [18] 0 0
Lima
Country [19] 0 0
South Africa
State/province [19] 0 0
Durban
Country [20] 0 0
Spain
State/province [20] 0 0
Barcelona
Country [21] 0 0
Switzerland
State/province [21] 0 0
Basel
Country [22] 0 0
United Kingdom
State/province [22] 0 0
Hull

Funding & Sponsors
Primary sponsor type
Other
Name
Hamilton Health Sciences Corporation
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
McMaster University
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
P.J. Devereaux, MD, PhD
Address 0 0
Population Health Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents


Results are available at https://clinicaltrials.gov/study/NCT01082874